Related Experiment Video
Updated: Jan 11, 2026
In vivo Macrophage Imaging Using MR Targeted Contrast Agent for Longitudinal Evaluation of Septic Arthritis
Published on: October 20, 2013
Natural Macrophage Membrane-Coated Nanoparticles as a Multifaceted Sepsis Therapeutic to Sequester Inflammatory and
Alexandria Hoffman1, Elisabet Bjånes1, Zhidong Zhou2
1Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California San Diego, La Jolla, California 92093, United States.
Abstract:
Bacterial sepsis is a life-threatening immune dysregulation triggered by bacterial infection and propagated by a dysfunctional host response, culminating in systemic tissue damage and multiorgan failure. In the United States, sepsis results in the hospitalization of more than one million patients annually and accounts for nearly one in three hospital deaths. Despite decades of efforts to develop immunoregulatory sepsis therapies, no clinically approved treatments exist. Recent advances in nanotechnology have introduced innovative approaches, including cellular nanodecoys synthesized from natural macrophage membranes coated onto polymeric nanoparticle cores. Here we introduce a human macrophage membrane-derived drug candidate, CTI-111, capable of sequestering soluble microbial toxins, drivers of inflammation, and pro-inflammatory cytokines from multiple sources. Therapeutic administration of CTI-111 reduces inflammation and improves survival in multiple murine sepsis models. We further demonstrate that CTI-111 can bind multiple sepsis-associated human cytokines in the complex environment of septic serum ex vivo. Together, these findings highlight the potential of CTI-111 as a multifaceted therapy for sepsis.
Insights
A novel nanotechnology-based therapy, CTI-111, effectively neutralizes toxins and inflammatory cytokines in sepsis models. This macrophage membrane-derived drug candidate shows promise for treating sepsis by reducing inflammation and improving survival rates.
Area of Science:
- Immunology
- Nanotechnology
- Pharmacology
Background:
- Sepsis is a critical condition with high mortality, characterized by immune dysregulation and organ failure.
- Current sepsis treatments are limited, with no approved immunoregulatory therapies available.
- Nanotechnology offers new therapeutic avenues, such as cellular nanodecoys.
Purpose of the Study:
- To introduce CTI-111, a novel drug candidate derived from human macrophage membranes.
- To evaluate the efficacy of CTI-111 in sequestering sepsis-related toxins and cytokines.
- To assess CTI-111's therapeutic potential in preclinical sepsis models.
Main Methods:
- CTI-111 synthesized using human macrophage membranes coated onto nanoparticle cores.
- In vitro assessment of CTI-111's binding capacity for human cytokines in septic serum.
- In vivo evaluation of CTI-111 in multiple murine models of sepsis.
Main Results:
- CTI-111 successfully sequesters microbial toxins, inflammatory mediators, and cytokines.
- Therapeutic administration of CTI-111 significantly reduced inflammation in sepsis models.
- CTI-111 demonstrated improved survival rates in murine sepsis models.
- Ex vivo studies confirmed CTI-111's ability to bind human cytokines in septic serum.
Conclusions:
- CTI-111 exhibits multifaceted therapeutic potential for sepsis.
- The drug candidate effectively targets key inflammatory pathways involved in sepsis.
- CTI-111 represents a promising nanotechnology-based approach for sepsis treatment.
More Related Videos
09:51Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
09:36Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo
Published on: February 5, 2019
Related Concept Videos
01:25Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
01:38Inflammation